Scandinavian Biopharma has entered into an agreement with the United States Army Medical Research Acquisition Activity (USAMRAA) to support the production and development of the vaccine, with the long-term goal of preventing bacterial diarrhoea in war fighters.
In April this year, SBH announced the preliminary findings from a Phase 2b study of the oral vaccine ETVAX against travellers’ diarrhoea in Finnish travellers to Benin, West Africa.
Findings from a Phase 2b study
The preliminary results confirmed the safety and overall positive immunogenicity of ETVAX, states the company in its press release. “While not reaching our protective efficacy goal of 70%, we are pleased to see a significant protective efficacy (PE = 56%) against all severe diarrhoea, regardless of pathogen, most likely because ETEC was found in 75% of all severe diarrhoea cases. The broad significant protective efficacy (52%) seen against all ETEC and bacterial co-pathogens and parasites despite the very high overall presence of bacterial enteropathogens is a strong indication that the point-estimate in a cohort with less co-pathogens could be considerably higher.”
“We are proud to announce the FAR based agreement with USAMRAA. It is a great recognition of our achievements and validation of the remaining plans with the aim to license our vaccine ETVAX against ETEC caused diarrhoea,” says Björn Sjöstrand CEO at Scandinavian Biopharma.
Photo of Björn Sjöstrand: Scandinavian Biopharma
